Connective tissue diseases: Targeting B cells in SLE: Good news at last!

Nature Reviews Rheumatology

Volumn 7, Issue 5, 2011, Pages 255-256

  Sanz, Ĩaki ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; CD1D ANTIGEN; CD27 ANTIGEN; CD5 ANTIGEN; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN D; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 21; PLACEBO; RITUXIMAB;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CYTOKINE PRODUCTION; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; GENE OVEREXPRESSION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

EID: 79955634524     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.48     Document Type: Article

References (10)

1. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721-731 (2011).
2. Manzi, S. et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase 3 BLISS-52 and -76 studies [abstract 1456]. Arthritis Rheum. 62 (Suppl.), S607 (2010).
3. US Food and Drug Administration. FDA approves Benlysta to treat lupus [online], http:// www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm246489. htm (2011).
4. Wallace, D. J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168-1178 (2009).
5. Stohl, W., Scholz, J. L. & Cancro, M. P. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr. Opin. Rheumatol. doi:10.1097/ BOR.0b013e328344c15e.
6. Yurasov, S. et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201, 703-711 (2005). (Pubitemid 40395116)
7. Jacobi, A. M. et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 62, 201-210 (2010).
8. Blair, P. A. et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129-140 (2010).
9. Yang, M. et al. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J. Immunol. 184, 3321-3325 (2010).
10. Iwata, Y. et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117, 530-541 (2011).